{
    "clinical_study": {
        "@rank": "80679", 
        "arm_group": [
            {
                "arm_group_label": "Paclitaxel liposome and Cisplatin", 
                "arm_group_type": "Experimental", 
                "description": "Drug: paclitaxel liposome 175mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles:up to 6 cycles.\nDrug: cisplatin 37.5 mg/m2, IV (in the vein) on day 1~2 of each 21 day cycle. Number of Cycles: up to 6 cycles."
            }, 
            {
                "arm_group_label": "Cisplatin plus 5-fluorouracil", 
                "arm_group_type": "Active Comparator", 
                "description": "Cisplatin:\n37.5 mg/m2, IV (in the vein) on day 1-2 of each 21 day cycle. Number of Cycles: up to 6 cycles.\n5-fluorouracil: 200mg/m2, CIV (continuous intravenous infusion) on day 1~5 of each 21 day cycle. Number of Cycles: up to 6 cycles."
            }
        ], 
        "brief_summary": {
            "textblock": "There are no standard chemotherapy regimens for metastatic esophageal cancer. Cisplatin plus\n      5-fluorouracil is widely used as first-line treatment with a response rate ranged from 30%\n      to 40%. Combination of paclitaxel and cisplatin has been investigated in small size clinical\n      trial, producing promising outcome.Liposome capsuled paclitaxel has been proved to be as\n      effective as paclitaxel.The usefulness of the the regimen of paclitaxel liposome with\n      cisplatin is evaluated by median survival time, progression free survival,and response rate."
        }, 
        "brief_title": "Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer", 
        "condition": "Esophageal Cancer", 
        "condition_browse": {
            "mesh_term": "Esophageal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed metastatic esophageal tumors with no previous treatment for\n             advanced disease or recurrent disease after previous treatment for at least one year.\n\n          -  At least one measurable lesion according to the RECIST1.1 (Response Evaluation\n             Criteria in Solid Tumors RECIST Version 1.1) criteria. Minimum indicator lesion size:\n             > 10 mm measured by spiral CT or >20mm measured by conventional techniques.\n\n          -  Patients aged between 18 and 70 years, inclusive, at the time of acquisition of\n             informed consent\n\n          -  Patients with performance status(ECOG) 0 to 1.\n\n          -  Abnormal hematologic values (WBC \u2265 3.0 x 109/L, Hemoglobin \u2265 10.0g/dl, platelet count\n             \u2265 100 x 109/L)\n\n          -  Creatinine clearance \u2265 60 ml/min, Serum creatinine \u2264 1.5mg/dl\n\n          -  Serum bilirubin \u2264 1.5mg/dl. ALT(Alanine transaminase ), AST(Aspartate Transaminase) \u2264\n             2.5 x upper normal limit (or \u2264 2.5 x upper normal limit in the case of liver\n             metastases)\n\n          -  Life expectancy \u2265 3 months\n\n          -  Patients who have given written informed consent to participate in this study\n\n        Exclusion Criteria:\n\n          -  Patients with active multiple cancers; or even if the multiple cancers are\n             metachronous, have a disease-free period of less than 5 years (but excluding cancer\n             in situ and skin cancer)\n\n          -  Serious, uncontrolled, concurrent infection(s) or illness(es)\n\n          -  Patients with no serious concurrent complications (such as heart disease, Intestinal\n             pneumonia)\n\n          -  Patients with brain metastasis\n\n          -  Patients receiving continuous administration of steroids\n\n          -  Patients who have experienced serious drug allergy in the past\n\n          -  Patients with retention of body fluid(pleural effusion, ascites, pericardial\n             effusion) necessitating treatment\n\n          -  Patients who are pregnant and lactating or hope to become pregnant during the study\n             period\n\n          -  Patients with prior Taxane treatment (Paclitaxel)\n\n          -  Others, patients judged by the investigator or coinvestigator to be inappropriate as\n             subject"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "202", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01998347", 
            "org_study_id": "CSMECS 01", 
            "secondary_id": "LYC01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Paclitaxel liposome and Cisplatin", 
                "intervention_name": "Paclitaxel liposome", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Paclitaxel liposome and Cisplatin", 
                    "Cisplatin plus 5-fluorouracil"
                ], 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cisplatin plus 5-fluorouracil", 
                "intervention_name": "5-fluorouracil", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cisplatin", 
                "Fluorouracil", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 23, 2013", 
        "location": {
            "contact": {
                "email": "linycst@gmail.com", 
                "last_name": "Xuyuan Li"
            }, 
            "facility": {
                "address": {
                    "city": "Shantou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "515031"
                }, 
                "name": "Department of medical oncology,Cancer hospital of Shantou University Medical colledge"
            }, 
            "investigator": {
                "last_name": "Yingcheng Lin", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer: an Open-label, Randomised Phase 3 Trial.", 
        "other_outcome": {
            "measure": "time to progression", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "median overall survival", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01998347"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shantou University Medical College", 
            "investigator_full_name": "Lin Yingcheng", 
            "investigator_title": "deputy secretary", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "median progression free survival", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "source": "Shantou University Medical College", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shantou University Medical College", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}